abstract |
Disclosed herein is the use of a compound of formula (I) in the manufacture of a medicament for treating excessive osteolysis, by inhibiting M-CSF mediated osteoclast development. These compounds also are useful for inhibiting phosphorylation of CSF1R, and for treating cancers that express CSF1R. |